Tuesday Apr 8
ImmunoGen, Inc. Announces First Clinical Findings with Refined Dosing Strategy for IMGN853
The data were presented at the American Association for Cancer Research Annual Meeting in San Diego, CA.
Immunogen Rating Increased to Outperform at Zacks
The firm currently has a $15.90 target price on the stock. Zacks 's price objective suggests a potential upside of 19.64% from the company's previous close.
ImmunoGen Schedules Presentations by Company Scientists at Upcoming AACR Annual Meeting
"They also include highly encouraging preclinical findings with both our IMGN289 and IMGN853 compounds, as well as data on some of the more recent additions to our ADC technology portfolio."
Immunogen CEO Sells $246,000 in Stock
Immunogen CEO Daniel M. Junius sold 15,000 shares of the stock on the open market in a transaction that occurred on Monday, March 17th.
ImmunoGen, Inc. Announces Presentations by Company Scientists at Upcoming AACR Annual Meeting
'The presentations scheduled include the pharmacokinetics modeling work which informed our decision to dose IMGN853 based on adjusted ideal body weight and to assess it dosed weekly,' commented , Ph.D., Executive Vice President and Chief Scientific Officer.